183
Views
11
CrossRef citations to date
0
Altmetric
Case Reports

A case of granulomatous rosacea successfully treated with pimecrolimus cream

, , , , , & show all
Pages 313-315 | Received 08 Feb 2008, Accepted 12 Feb 2008, Published online: 12 Jul 2009

References

  • Weissenbacher S., Merkl J., Hildebrandt B., Wollenberg A., Braeutigam M., Ring J., et al. Pimecrolimus cream 1% for papulopustular rosacea: A randomized vehicle‐controlled double‐blind trial. Br J Dermatol 2007; 156: 728–32
  • Pelle M. T., Crawford G. H., James W. D. Rosacea II. Therapy. J Am Acad Dermatol 2004; 51: 499–512
  • Buechner S. A. Rosacea: An update. Dermatology 2005; 210: 100–8
  • Cunha P. R., Rossi A. B. Pimecrolimus cream 1% is effective in a case of granulomatous rosacea. Acta Derm Venereol 2006; 86: 71–2
  • Crawford G. H., Pelle M. T., James W. D. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2005; 46: 584–7
  • Goldman D. Tacrolimus ointment for the treatment of steroid‐induced rosacea: A preliminary report. J Am Acad Dermatol 2001; 44: 995–8
  • Chu C. Y. The use of 1% pimecrolimus cream for the treatment of steroid‐induced rosacea. Br J Dermatol 2005; 152: 396–9
  • Chu C. Y. An open‐label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid‐induced rosacea‐like eruption. J Eur Acad Dermatol Venereol 2007; 21: 484–90

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.